Brief: Timber Pharmaceuticals - Positive Top-Line Results From Phase 2B Control Study Evaluating Tmb-001 In Moderate To Severe Congenital Ichthyosis
07/10/2021 14:08
Oct 7 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS - POSITIVE TOP-LINE RESULTS FROM
PHASE 2B
CONTROL STUDY EVALUATING TMB-001 IN MODERATE TO SEVERE
CONGENITAL ICHTHYOSIS
Source text for Eikon: ID:
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing